Pune’s Mylab is now part of Harvard Business Review’s case collection

The case study titled, ‘Mylab Discovery Solutions: Innovating against all Odds’, focuses on how Mylab's founders steered the company through the Covid-19 pandemic.

pune mylab, harvard business review, indian express

Harvard Business Review has included in its case collection a study of Mylab Discovery Solutions' innovations conducted by the IIM-Bangalore. (File)

Listen to this article

Pune’s Mylab is now part of Harvard Business Review’s case collection

00:00

1x 1.5x 1.8x

Harvard Business Review has included in its case collection a study of Mylab Discovery Solutions‘ innovations conducted by the IIM-Bangalore, the Pune-based biotech firm, which made a mark during the pandemic with its Covid-19 test kits, said Wednesday.

The case study titled, ‘Mylab Discovery Solutions: Innovating against all Odds’, focuses on how Mylab’s founders steered the company through the Covid-19 pandemic, taking their production from 10,000 tests to 5,50,000 per week and employee strength from 30 to 350.

According to the case study, prepared by Charu Rastogi (PhD student at IIMB), Prof Srivardhini K Jha (IIMB) and Rishikesha Krishnan (Director, IIMB), the company’s “fortunes changed in March 2020, when the Covid-19 pandemic struck. The firm was dubbed the ‘poster child of the Covid-19 pandemic’ after it rose to the limelight for developing Covid-19 RTPCR and rapid antigen test kits”.

Also Read |Pune-based Mylab showcases test kits at One World TB Summit

It adds, “The firm started developing RTPCR and rapid antigen test kits and the next two years saw it raising funds, automating and scaling production, doubling down on research and development, launching multiple new products, and pursuing inorganic growth through acquisitions and alliances.”

When contacted, Hasmukh Rawal, MD, Mylab, told, The Indian Express, “During the initial years, we met with several challenges, including the lack of a level playing field in high-end diagnostics, slow adoption rate of molecular testing, long gestation period from conceptualisation to regulatory approval prior to commercialisation and immense lack of funding to support the research and manufacturing of innovations.”

Don't miss |Pune-based Mylab expands its presence in UAE, Kuwait through joint venture

Rawal added, “Following the pandemic, we have been deploying various alternatives in the diagnostics space for consolidating the company’s position in the domestic market and to maintain its growth momentum by expanding to new product lines as well as new geographies.”